- Home
- ONON vs MDGL Comparison
ONON vs MDGL Comparison
Compare ONON & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONON
- MDGL
- Stock Information
- Founded
- ONON 2010
- MDGL 2011
- Country
- ONON Switzerland
- MDGL United States
- Employees
- ONON N/A
- MDGL N/A
- Industry
- ONON Shoe Manufacturing
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- ONON Consumer Discretionary
- MDGL Health Care
- Exchange
- ONON Nasdaq
- MDGL Nasdaq
- Market Cap
- ONON 11.4B
- MDGL 9.6B
- IPO Year
- ONON 2021
- MDGL N/A
- Fundamental
- Price
- ONON $42.29
- MDGL $587.32
- Analyst Decision
- ONON Strong Buy
- MDGL Strong Buy
- Analyst Count
- ONON 20
- MDGL 13
- Target Price
- ONON $62.75
- MDGL $543.33
- AVG Volume (30 Days)
- ONON 10.7M
- MDGL 470.4K
- Earning Date
- ONON 11-12-2025
- MDGL 11-04-2025
- Dividend Yield
- ONON N/A
- MDGL N/A
- EPS Growth
- ONON 74.51
- MDGL N/A
- EPS
- ONON 0.84
- MDGL N/A
- Revenue
- ONON $3,607,815,596.00
- MDGL $740,640,000.00
- Revenue This Year
- ONON $30.53
- MDGL $395.75
- Revenue Next Year
- ONON $23.83
- MDGL $65.73
- P/E Ratio
- ONON $49.45
- MDGL N/A
- Revenue Growth
- ONON 33.26
- MDGL 864.21
- 52 Week Low
- ONON $34.38
- MDGL $265.00
- 52 Week High
- ONON $64.05
- MDGL $594.99
- Technical
- Relative Strength Index (RSI)
- ONON 55.88
- MDGL 74.69
- Support Level
- ONON $40.45
- MDGL $535.00
- Resistance Level
- ONON $43.57
- MDGL $594.99
- Average True Range (ATR)
- ONON 1.90
- MDGL 28.63
- MACD
- ONON 0.49
- MDGL 6.39
- Stochastic Oscillator
- ONON 73.93
- MDGL 93.69
About ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.